Last updated: August 1, 2026
Locoid Lipocream is a topical corticosteroid containing hydrocortisone butyrate 0.1%. The product is approved in the United States for corticosteroid-responsive dermatoses, including atopic dermatitis, contact dermatitis, seborrheic dermatitis and psoriasis. Its commercial outlook is constrained by mature generic competition, limited clinical differentiation and the availability of multiple lower-cost topical corticosteroids. Growth opportunities are concentrated in branded dermatology prescribing, pediatric use, vehicle preference and non-U.S. markets.
What is Locoid Lipocream and what is it approved to treat?
Locoid Lipocream contains hydrocortisone butyrate, a medium-potency topical corticosteroid formulated as a lipophilic cream. The product is applied to affected skin as directed, generally in a thin film. The FDA label identifies corticosteroid-responsive dermatoses as the indication and limits use according to potency, treatment area, duration and patient age.[1]
| Attribute |
Locoid Lipocream |
| Active ingredient |
Hydrocortisone butyrate |
| Strength |
0.1% |
| Dosage form |
Topical cream |
| Pharmacologic class |
Corticosteroid |
| FDA status |
Prescription drug |
| Main therapeutic area |
Dermatology |
| Common target conditions |
Atopic dermatitis, eczema, contact dermatitis, seborrheic dermatitis and psoriasis |
| Route |
Topical |
| U.S. regulatory pathway |
New Drug Application, followed by generic ANDA competition |
| Biosimilar relevance |
None; Locoid is a small-molecule topical drug |
Locoid Lipocream is distinct from lower-potency hydrocortisone products and from high-potency agents such as clobetasol. Hydrocortisone butyrate 0.1% occupies a middle segment in topical corticosteroid prescribing, where clinicians balance anti-inflammatory activity against skin atrophy and other local adverse effects.
What is the latest clinical-trial status for Locoid Lipocream?
No late-stage clinical development program is associated with Locoid Lipocream. The product is a mature, approved topical medicine, and its current commercial strategy is based on prescription sales rather than new efficacy development.
The pivotal evidence supporting hydrocortisone butyrate topical products predates the modern ClinicalTrials.gov reporting environment. The FDA-approved labeling describes clinical experience in corticosteroid-responsive dermatoses and pediatric studies. The label reports exposure in pediatric patients, including infants and children, with monitoring for local corticosteroid effects and hypothalamic-pituitary-adrenal-axis suppression.[1]
Clinical-trial activity and development status
| Development category |
Current assessment |
| Phase 2 or Phase 3 Locoid Lipocream trial |
No active branded development program identified |
| New indication program |
None publicly established |
| Pediatric development |
Existing label-supported pediatric safety data |
| Comparative efficacy program |
No current pivotal program identified |
| Reformulation program |
No publicly established late-stage program |
| Clinical focus |
Routine postmarketing use rather than active development |
The absence of a current trial pipeline reflects the product’s age and generic status. Any future clinical activity would more likely involve a new vehicle, combination product, pediatric formulation, over-the-counter switch strategy or a new delivery system than a conventional efficacy trial for the existing cream.
How effective is Locoid Lipocream compared with other topical steroids?
Hydrocortisone butyrate 0.1% is generally used when a clinician requires more activity than low-potency hydrocortisone but wants to avoid the exposure profile of very potent corticosteroids. Efficacy depends on the disease, body site, severity, adherence and formulation.
| Product category |
Representative drugs |
Relative commercial position |
| Low potency |
Hydrocortisone 1%, desonide |
Broad generic competition; often first-line for sensitive areas |
| Medium potency |
Hydrocortisone butyrate, triamcinolone acetonide |
Large generic market; Locoid competes through brand and vehicle |
| High potency |
Fluocinonide, betamethasone dipropionate |
Used for thicker or more resistant plaques |
| Very high potency |
Clobetasol propionate |
Short-course treatment for severe localized disease |
Locoid Lipocream’s main clinical differentiator is the product vehicle rather than a novel active ingredient. A cream vehicle may be preferred for inflamed or moist lesions, while ointments provide greater occlusion and emollience. Lotions, solutions and foams can be more convenient for scalp or hair-bearing areas.
What is the FDA regulatory status of Locoid Lipocream?
Locoid Lipocream is an FDA-approved prescription product. The approval is associated with hydrocortisone butyrate topical therapy and is separate from the regulatory status of generic hydrocortisone butyrate cream products.
The label includes standard corticosteroid warnings involving:
- Local adverse reactions such as burning, stinging, irritation, dryness, folliculitis and skin atrophy.
- Systemic absorption, particularly with large treatment areas, prolonged use, occlusion or use on damaged skin.
- Pediatric susceptibility to systemic exposure because of a higher skin-surface-area-to-body-weight ratio.
- Potential effects on growth, weight gain and the hypothalamic-pituitary-adrenal axis in susceptible children.
- Avoidance of use in untreated bacterial, viral, fungal or parasitic skin infections.
The FDA label also states that topical corticosteroids should be used during pregnancy only when the potential benefit justifies potential fetal risk. Breastfeeding use requires care to prevent infant exposure, particularly when the product is applied to the breast.[1]
What patents protect Locoid Lipocream?
The commercial protection for Locoid Lipocream is primarily based on historical formulation and regulatory exclusivity rather than an active, high-value patent estate.
Hydrocortisone butyrate is an established corticosteroid. The active ingredient is not a new chemical entity, and the product has been marketed for decades. Any historical patents covering the active compound or early formulations have long passed their ordinary term. Current competitive protection is more likely to arise from:
- Formulation claims covering a specific cream vehicle.
- Manufacturing specifications.
- Product trade dress and branding.
- Regulatory requirements for generic approval.
- Prescription-channel relationships and physician familiarity.
The U.S. generic market includes hydrocortisone butyrate topical products, which materially weakens any residual exclusivity associated with the branded cream. Product-specific Orange Book patent protection should be confirmed against the current FDA Orange Book record for the relevant NDA and supplement because listings can change with transfers, delistings and product-status updates.[2]
How strong is the patent estate for Locoid Lipocream?
The patent estate is commercially weak relative to newer dermatology products protected by active composition-of-matter, formulation or method-of-use patents. The principal barriers to generic entry are no longer expected to be patent-based. They are more likely to involve:
- FDA approval requirements for topical semisolid products.
- Demonstration of pharmaceutical equivalence.
- Formulation and manufacturing reproducibility.
- Product availability and pharmacy substitution.
- Brand recognition in dermatology practices.
Are there Paragraph IV challenges to Locoid Lipocream?
Generic hydrocortisone butyrate products have entered the U.S. market, indicating that the principal market-entry barrier for the established product has already been overcome. No major, current Paragraph IV dispute is a central commercial issue for Locoid Lipocream.
For a mature topical product, an ANDA applicant may rely on certification that listed patents have expired, are not applicable, or will not be infringed. Generic competition can also arise after the relevant patent term has ended without a material Paragraph IV litigation event.
| Litigation issue |
Commercial assessment |
| Active patent lawsuit affecting U.S. entry |
No major current dispute identified |
| Generic hydrocortisone butyrate cream |
Available in the U.S. market |
| Paragraph IV risk to the brand |
Low as a new-event risk; generic erosion is established |
| Settlement agreement |
No major current settlement controlling market entry identified |
| Litigation value |
Limited compared with newer branded dermatology drugs |
What formulations are protected or commercially differentiated?
The cream vehicle is the main product-level differentiator. Hydrocortisone butyrate is also available in other topical dosage forms, including ointment and lotion presentations in certain markets or product lines. These products are not interchangeable from a patient-experience or prescribing perspective, even when the active ingredient and strength are similar.
Formulation factors affecting competition
- Emollient feel and spreadability.
- Absorption and residence time on the skin.
- Cosmetic acceptability.
- Ease of application over large areas.
- Suitability for pediatric patients.
- Suitability for intertriginous or sensitive sites.
- Stability and preservative system.
- Tube or pump packaging.
- Wholesale acquisition price and pharmacy reimbursement.
A generic cream that matches the active ingredient and strength can still compete on price without matching every brand attribute. Conversely, a branded product can preserve some demand if prescribers believe the vehicle improves adherence or tolerability.
How does Locoid Lipocream compare with competing dermatology drugs?
Locoid Lipocream competes in a crowded market that includes generic corticosteroids, branded nonsteroidal therapies and newer biologics for atopic dermatitis and psoriasis.
| Competitor |
Active ingredient or class |
Competitive effect on Locoid |
| Generic hydrocortisone butyrate |
Same active ingredient |
Direct price substitution |
| Triamcinolone acetonide |
Medium-potency corticosteroid |
Broad generic alternative |
| Desonide |
Low-potency corticosteroid |
Competes in pediatric and sensitive-site use |
| Fluocinolone acetonide |
Low-to-medium potency |
Alternative for eczema and inflammatory dermatoses |
| Tacrolimus ointment |
Topical calcineurin inhibitor |
Nonsteroidal alternative for selected sites |
| Pimecrolimus cream |
Topical calcineurin inhibitor |
Competes in mild-to-moderate atopic dermatitis |
| Ruxolitinib cream |
Topical JAK inhibitor |
Branded nonsteroidal alternative in atopic dermatitis and vitiligo |
| Crisaborole |
PDE-4 inhibitor |
Nonsteroidal branded alternative |
| Dupilumab |
Biologic |
Systemic or injectable option for moderate-to-severe atopic dermatitis |
The strongest direct pressure comes from generic hydrocortisone butyrate and triamcinolone products. Newer nonsteroidal agents affect the higher-value segment of the market, particularly when clinicians seek steroid-sparing treatment or treatment for chronic disease.
What is the commercial and market outlook for Locoid Lipocream?
Public companies generally do not report Locoid Lipocream revenue as a separate line item. The product is part of a broader dermatology portfolio, and reported sales are often aggregated across brands, geographies or dosage forms.
The market outlook is therefore best assessed through product maturity, prescription volume, generic share and pricing rather than a standalone audited revenue series.
Market drivers
- Persistent prevalence of atopic dermatitis and eczema.
- Continued use of topical corticosteroids as first-line therapy.
- Pediatric dermatology demand.
- Low manufacturing complexity compared with biologics.
- Physician familiarity with hydrocortisone butyrate.
- Potential demand for branded vehicles in patients with adherence or tolerability concerns.
Market restraints
- Generic substitution.
- Low active-ingredient differentiation.
- Reimbursement pressure.
- Availability of lower-cost medium-potency corticosteroids.
- Movement toward steroid-sparing therapies.
- Limited potential for premium pricing.
- Lack of new indication expansion.
Revenue exposure
Locoid Lipocream’s revenue exposure is likely concentrated in:
- Prescription dermatology.
- Retail and specialty pharmacies.
- Patients who retain the brand despite generic availability.
- Markets where the specific vehicle or brand remains commercially supported.
The product has limited exposure to hospital purchasing and no meaningful exposure to biosimilar substitution. Its risk is generic erosion, not biologic competition.
What are the projected sales scenarios for Locoid Lipocream?
A product-specific forecast should use prescription volume, net price, generic substitution and geographic revenue. Because the product is mature and standalone revenue is not generally disclosed, a directional scenario is more appropriate than a single-point forecast.
| Scenario |
2025-2027 outlook |
2028-2030 outlook |
Main assumptions |
| Downside |
Low-single-digit annual decline |
Mid-single-digit annual decline |
Continued generic substitution, lower reimbursement and limited promotion |
| Base case |
Flat to low-single-digit decline |
Low-single-digit decline |
Stable clinical use offsets part of price erosion |
| Upside |
Low-single-digit growth |
Flat to low-single-digit growth |
Strong brand retention, vehicle preference and expansion in selected markets |
The base case is a mature-brand erosion profile. Volume can remain relatively stable because topical corticosteroids are entrenched in clinical practice, but net sales can decline as generic prices and substitution increase.
A durable growth trajectory would require one of four developments:
- A differentiated reformulation.
- A new delivery system.
- Expanded geographic commercialization.
- A branded positioning strategy supported by evidence of improved adherence, tolerability or patient satisfaction.
Which companies are challenging Locoid Lipocream?
The competitive field includes generic manufacturers of hydrocortisone butyrate cream and manufacturers of substitute topical corticosteroids. Generic competition is fragmented and can change as ANDA holders enter, exit or transfer products.
Relevant competitor groups include:
- Generic hydrocortisone butyrate manufacturers.
- Generic triamcinolone acetonide manufacturers.
- Generic desonide manufacturers.
- Branded nonsteroidal topical-drug companies.
- Biologic manufacturers serving moderate-to-severe atopic dermatitis.
The most important competitive distinction is between same-ingredient substitution and therapeutic substitution. Same-ingredient substitution places direct pressure on Locoid Lipocream pricing. Therapeutic substitution affects prescribing decisions before the prescription is written.
What generic launch risks exist for Locoid Lipocream?
Generic launch risk is already realized rather than prospective. The product’s principal risks are continued erosion of brand share, pharmacy substitution and reduced payer willingness to reimburse a premium.
Generic entry factors
- FDA approval of hydrocortisone butyrate cream ANDAs.
- Availability of a pharmaceutically equivalent product.
- State substitution laws.
- Formulary placement.
- Wholesale pricing.
- Prescriber brand preference.
- Patient response to the vehicle.
Topical semisolid products can present manufacturing and equivalence challenges because performance depends on the vehicle, particle or globule characteristics, viscosity, pH and release behavior. Those factors can slow individual generic development, but they do not create durable exclusivity once multiple equivalent products are approved.
What manufacturing and intellectual-property barriers affect Locoid Lipocream?
Manufacturing barriers are moderate. The active ingredient is established, but cream production requires controlled emulsification, uniform active distribution, viscosity control, microbial protection and packaging compatibility.
The most relevant manufacturing risks include:
- Batch-to-batch consistency.
- Uniformity of hydrocortisone butyrate concentration.
- Emulsion stability.
- Preservative performance.
- In-vitro release and permeation behavior.
- Tube filling and container closure.
- Scale-up from laboratory to commercial production.
These factors can influence FDA review and product quality. They do not normally support the long-term pricing power associated with a patented active ingredient or complex biologic manufacturing process.
What is the geographic market outlook?
The U.S. market is mature and genericized. Commercial opportunity is stronger in countries where:
- Hydrocortisone butyrate has established prescription use.
- The Locoid brand remains recognized.
- Generic substitution is less aggressive.
- Dermatology reimbursement supports branded topical products.
- Local regulatory approval covers the same formulation or an equivalent presentation.
European and other international markets may use different brand names, pack sizes, formulations or marketing authorization holders. Regulatory status should therefore be assessed country by country rather than inferred from U.S. approval.
Key Takeaways
- Locoid Lipocream contains hydrocortisone butyrate 0.1%, a medium-potency topical corticosteroid.
- It is an established FDA-approved dermatology product with no visible late-stage clinical development program.
- Pediatric use is supported by label-described safety experience, but topical corticosteroid exposure requires site, duration and area controls.
- Generic hydrocortisone butyrate products create direct price and share pressure.
- The commercial differentiator is the cream vehicle and brand familiarity, not a novel active ingredient.
- Patent-based exclusivity is limited for a product of this age; current risk is generic erosion rather than new Paragraph IV litigation.
- Standalone revenue is generally not publicly disclosed.
- The base-case forecast is flat to low-single-digit annual decline, with upside requiring reformulation, new delivery technology or stronger geographic penetration.
- Biosimilar risk is not relevant because Locoid Lipocream is a small-molecule topical drug.
- Manufacturing complexity is moderate and can affect generic development, but it is unlikely to preserve durable premium pricing.
FAQs
Is Locoid Lipocream stronger than hydrocortisone cream?
Yes. Locoid Lipocream contains hydrocortisone butyrate 0.1%, which is generally classified as a medium-potency topical corticosteroid. Over-the-counter hydrocortisone 1% is typically considered low potency.
Can generic hydrocortisone butyrate replace Locoid Lipocream?
Generic hydrocortisone butyrate cream may provide a direct alternative when the strength, dosage form and clinical use are equivalent. Substitution depends on FDA equivalence, state law, payer policy and the prescriber’s instructions.
Does Locoid Lipocream have biosimilar competition?
No. Biosimilar rules apply to biologic products. Locoid Lipocream contains a chemically synthesized small-molecule corticosteroid and competes with generic drugs.
Is Locoid Lipocream used for atopic dermatitis in children?
Yes. The FDA labeling includes pediatric safety information and identifies corticosteroid-responsive dermatoses as the therapeutic setting. Pediatric treatment requires careful control of application area, treatment duration and occlusion.[1]
Could Locoid Lipocream become an over-the-counter product?
An over-the-counter switch would require FDA review of the active ingredient, concentration, labeling, consumer ability to self-diagnose and safe self-use. No established FDA switch program for Locoid Lipocream is identified.
References
-
U.S. Food and Drug Administration. (n.d.). Locoid Lipocream: Hydrocortisone butyrate cream, 0.1% prescribing information. FDA/DailyMed labeling.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.
-
National Library of Medicine. (2024). ClinicalTrials.gov. U.S. National Library of Medicine.
